In the case of neurodegenerative diseases, cells from the central system die out successively. When the brain is no longer capable of compensating this loss, NDDs such as Parkinson’s, dementia, strokes, or Alzheimer’s result from it.
The risk of developing NDDs was rising steadily, but the COVID-19 pandemic has accelerated the process, which could lead to a global health crisis.
When it comes to therapy, there is no progress to be seen: NDDs have been only treated symptomatically in the last 30 years. There are not any causal therapies nor are there preventive vaccinations.
Lack of investments: many pharmaceutical companies have retracted their investments in research and treatment for NDDs. The market is failing, and the needs of society are not met.
Complexity of neurodegenerative diseases: Parkinson’s disease applies as multisystemic and multicausal. Thus, research is lengthy and costly.
We expect medical, social, and economic challenges which make decisive deals imperative.
We are lacking both a targeted use of technologies and a determined implementation of basic research leading to healing therapies, as well as sufficient financial means and incentives for an innovative undertaking of the industry.
There is enough money in the market – the profits from the partaking companies and their shareholders for the vaccines against corona alone should suffice.
This leaves big pharmaceutical companies new opportunities to set in gear significant progress related to NDDs. The fonds would link private investments and public means. The goal would be, if successful, to gain financial benefits; the fight against NDDs becomes investment worthy.